GSK, Relation Therapeutics ink up to $110 million AI drug discovery deal

• Relation will create large-scale datasets showing how human cells respond to genetic and drug interventions, using the data to train AI foundation models including its MORGAN platform
• The collaboration expands upon previous work between the companies focused on fibrotic diseases and osteoarthritis
• GSK is increasing R&D investment to strengthen its drug pipeline and expanding AI use to improve efficiency and success rates in drug discovery

GSK and Relation Therapeutics Announce $110M AI Drug Discovery Partnership

British biotech company Relation Therapeutics announced Wednesday a research collaboration with pharmaceutical giant GSK valued at up to $110 million, focused on leveraging artificial intelligence for drug target identification.

Key Deal Terms:

Under the agreement, Relation Therapeutics will generate large-scale datasets documenting human cellular responses to genetic and drug interventions. This data will train AI foundation models, including Relation's proprietary MORGAN platform, to identify promising new drug targets.

Strategic Context:

The collaboration expands an existing partnership between the two companies that previously focused on fibrotic diseases and osteoarthritis. This deepening relationship reflects GSK's broader strategy to increase R&D investment and strengthen its drug pipeline through AI-enhanced discovery processes.

Market Implications:

The deal underscores the pharmaceutical industry's accelerating adoption of AI technologies to improve drug discovery efficiency and success rates. For GSK, this represents a continuation of its efforts to modernize research capabilities and rebuild its development pipeline. The partnership positions both companies at the intersection of biotechnology and artificial intelligence, a rapidly growing sector in pharmaceutical development.

The collaboration highlights the growing value of AI-driven platforms in early-stage drug discovery, where identifying viable targets remains a critical bottleneck. By combining Relation's AI expertise with GSK's pharmaceutical resources and market reach, the partnership aims to accelerate the traditionally lengthy and expensive drug development process.

This announcement comes as major pharmaceutical companies increasingly turn to AI partnerships and acquisitions to enhance their competitive positions in drug discovery.